Neurovance Reports Positive Phase 2 Results For Non-Stimulant ADHD Drug

Neuroscience-focused clinical stage company Neurovance reported positive results from the Phase IIA pilot study of its non-stimulant drug for ADHD, EB-1020 SR, in adult male patients with all ADHD subtypes.

from Content Keyword RSS http://ift.tt/1mSnCou http://ift.tt/eA8V8J

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s